Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas.
Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas.
复制标题
DOI：
10.1136/jitc-2023-006959
复制
发表时间：
2023-08
影响因子：
10.9
通讯作者：
中科院分区：
文献类型：
--
作者：
Chimeric antigen receptor (CAR)-T cells targeting CD30 have demonstrated high response rates with durable remissions observed in a subset of patients with relapsed/refractory CD30+ hematologic malignancies, particularly classical Hodgkin lymphoma. This therapy has low rates of toxicity including cytokine release syndrome with no neurotoxicity observed in our phase 2 study. We collected patient-reported outcomes (PROs) on patients treated with CD30 directed CAR-T cells to evaluate the impact of this therapy on their symptom experience. We collected PROs including PROMIS (Patient-Reported Outcomes Measurement Information System) Global Health and Physical Function questionnaires and selected symptom questions from the NCI PRO-CTCAE in patients enrolled on our clinical trial of CD30-directed CAR-T cells at procurement, at time of CAR-T cell infusion, and at various time points post treatment. We compared PROMIS scores and overall symptom burden between pre-procurement, time of infusion, and at 4 weeks post infusion. At least one PRO measurement during the study period was found in 23 out of the 28 enrolled patients. Patient overall symptom burden, global health and mental health, and physical function were at or above baseline levels at 4 weeks post CAR-T cell infusion. In addition, PROMIS scores for patients who participated in the clinical trial were similar to the average healthy population. CD30 CAR-T cell therapy has a favorable toxicity profile with patient physical function and symptom burden recovering to at least their baseline pretreatment health by 1 month post infusion. Trial registration number: NCT02690545.
登录
查看更多内容
DOI：
10.1182/hematology.2021000256
发表时间：
2021-12-10
影响因子：
3
作者：
Epperla, Narendranath;Hamadani, Mehdi
通讯作者：
Hamadani, Mehdi
DOI：
10.1200/edbk_320085
发表时间：
2021-03-01
期刊：
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
影响因子：
--
作者：
Gill, Saar;Brudno, Jennifer N
通讯作者：
Brudno, Jennifer N
影响因子：
3.6
作者：
Silveira, Augusta;Sequeira, Teresa;Goncalves, Joaquim;Ferreira, Pedro Lopes
通讯作者：
Ferreira, Pedro Lopes
影响因子：
158.5
作者：
Ansell, Stephen M.;Radford, John;Straus, David J.
通讯作者：
Straus, David J.
影响因子：
4.3
作者：
Ruark, Julia;Mullane, Erin;Bar, Merav
通讯作者：
Bar, Merav